Versanis Bio Announces Completion of Enrollment of the BELIEVE Phase 2b Study in Patients with Obesity
The global Phase 2b study assessing bimagrumab as a single agent and in combination with semaglutide in patients with obesity aims to evaluate its potential to substantially prevent the loss of muscle mass while reducing fat More than 500 patients have been enrolled in the trial, which is projected to read out mid-2024 NEW YORK, … Read more